http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#Head http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#assertion http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#provenance http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#pubInfo http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#assertion http://identifiers.org/drugbank/DB00334 http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Drug http://identifiers.org/drugbank/DB00334 http://www.w3.org/2000/01/rdf-schema#label Olanzapine http://identifiers.org/drugbank/DB00334 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.obolibrary.org/obo/MONDO_0005618 http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Disease http://purl.obolibrary.org/obo/MONDO_0005618 http://www.w3.org/2000/01/rdf-schema#label Anxiety disorder http://purl.obolibrary.org/obo/MONDO_0005618 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/MONDO_0005618 http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject http://identifiers.org/drugbank/DB00334 http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#association http://www.w3.org/2000/01/rdf-schema#label First, we estimated the change in the percentage of prescriptions for overall antipsychotics, FGA, and SGA for anxiety disorder visits from 2005 to 2013. We calculated the annual antipsychotic prescription rates as the total number of antipsychotic prescriptions divided by the total number of eligible patients with anxiety visits. The same patients are counted several times if they have several visits.We then stratified this 9-year dataset into three equal parts (2005–2007, 2008–2010, and 2011–2013) and examined the time trends in antipsychotic treatments during anxiety visits. We transformed the calendar years by subtracting 2005 from the year and dividing the results by 8. Thus, the transformed values were 0 for 2005 and 1 for 2013. The odds ratios associated with this transformed variable represent change in the odds of visits in which antipsychotic medication was prescribed across the entire study period (2005–2013). For example, an odds ratio of 2.0 denotes twice the odds that a visit included an antipsychotic at the end (2013) as compared with the start (2005) of the study period. Adjusted odds ratios (aOR) were calculated from the multivariate logistic model with adjustment for age and sex. We repeated similar analysis to examine the trends in the use of selective FGA (i.e., flupenxiol and sulpiride) and individual SGA (i.e., clozapine, risperidone, olanzapine, quetiapine, aripiprazole, and ziprasidone). (...) First-generation antipsychotics (FGA) use was more than that of second-generation antipsychotics (SGA) use in patients with anxiety disorder through the 9-year period. Sulpiride and flupentixol were the two most common FGA in the treatment of anxiety disorder. Patients with specific anxiety disorder (post-traumatic stress disorder, panic disorder/agoraphobia, generalized anxiety disorder, and obsessive-compulsive disorder), female sex, younger age (age < 65 years), comorbidity with major depression or minor depression, antidepressants concurrent use, and visits to psychiatrists, medical centers and primary care were significantly more likely to take prescribed antipsychotics http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#association https://w3id.org/biolink/vocab/aggregator_knowledge_source https://w3id.org/biolink/infores/knowledge-collaboratory http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#association https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#association https://w3id.org/biolink/vocab/has_population_context http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#context http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#association https://w3id.org/biolink/vocab/publications http://www.ncbi.nlm.nih.gov/pubmed/31077503 http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#association https://w3id.org/biolink/vocab/relation http://purl.obolibrary.org/obo/NCIT_C94303 http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#context http://www.w3.org/1999/02/22-rdf-syntax-ns#type https://w3id.org/biolink/vocab/Cohort http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#context http://www.w3.org/2000/01/rdf-schema#label Adults http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#context https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Cohort http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#provenance http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-7641-6446 http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#pubInfo http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#sig http://purl.org/nanopub/x/hasSignature V3wh44U5u0/9ZQtSh0QEZ9nYSwotFjRsGnzFdyoRh73/L9cql/W3A6XPijNCT/KITVrkcbspW/i50nJKwDPHLAqH2TWqLxlh5LBGBRVAchdOxIdqqDcAYTqruZY31vmZroosgbMKkIDOOruHfAGk8euBoVIDGgJXK6kynzeqZH4= http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38 http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38 http://www.w3.org/ns/prov#generatedAtTime 2022-09-16T11:51:08.822166 http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38 http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1501-1082 http://purl.org/np/RAqUZr9Tj5j5o5jVM2DL74gTyV40T4CZeq6GhupgtTG38 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY https://w3id.org/biolink/vocab/ http://purl.org/pav/version 2.3.0